KUALA LUMPUR, 13 August 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) held a fully virtual Meeting of Members today, which saw the shareholders voting to approve the 1-for-3 bonus share issuance which the Company had proposed on 3 May 2021.

The exercise will entail the issuance of 235,443,397 bonus shares in Duopharma Biotech on the basis of 1 bonus share for every 3 existing Duopharma Biotech shares held. The entitlement date will be announced at a later date.

Through the issuance of the bonus shares, Duopharma Biotech is enabling the shareholders to have greater participation in the equity of the group – in terms of the number of shares, while retaining their percentage of equity interest held. This will also improve the liquidity of Duopharma Biotech shares.

“The confidence of our shareholders has always been very important for Duopharma Biotech, and this bonus issue is another way we are rewarding them for their trust in us. We will continue to pursue new business opportunities that are suitable and promising, and strive towards stronger performance moving forward,” commented Duopharma Biotech Group Chairman Tan Sri Datin Paduka Siti Sa’diah Sh Bakir.